Experts Discuss Highlights from ESMO 2025
The 2025 European Society for Medical Oncology (ESMO) meeting highlighted several important prostate cancer findings that could soon influence patient care. In this video, Dr. Phillip Koo and Dr. Zachary Klaassen review the most significant takeaways from the conference, including:
- New data on hormone therapy options for men with high-risk localized disease—including who can safely stay on standard therapy and who may benefit from more intensive treatment alongside radiation.
- Treatment options for recurrent prostate cancer with a fast PSA doubling time– adding enzalutamide to standard hormone therapy reduced the risk of death by 40% in one study, while adding apalutamide to hormone therapy delayed treatment resistance.
- A new medicine for patients with specific gene changes–capivasertib delayed progression on scans when combined with abiraterone.
- Expanding use of lutetium–PSMA-617–currently used mainly in metastatic castration-resistant prostate cancer, this treatment showed benefit when given earlier to men with metastatic hormone-sensitive disease.
- The latest recommendations on genetic testing–both germline (inherited) and somatic (tumor) tests, plus a new PCF resource to help you understand these tests and talk to your doctor.
PCF thanks AstraZeneca for their support of this video.
